GEN Exclusives

More »

GEN News Highlights

More »
Nov 12, 2013

New Therapeutic Approach to Allergies and Asthma May Be on the Way

  • A collaboration among researchers in Israel and the United States has resulted in the discovery of a new pathway that has broad implications for treating allergic diseases—particularly eosinophil-associated disorders.

    Scientists from Tel Aviv University and Cincinnati Children's Hospital Medical Center have discovered how a specific molecular pathway kills eosinophils before they can cause havoc in the human body. Eosinophils are normal cellular components of the blood, but when the body produces too many they can cause a variety of eosinophilic disorders including allergic diseases such as asthma. These are disorders involving chronic inflammation resulting in tissue damage, often in the gastrointestinal system.

    The study (“Paired immunoglobulin-like receptor A is an intrinsic, self-limiting suppressor of IL-5–induced eosinophil development”) is published online in the journal Nature Immunology.

    “We demonstrate that IL-5 activity in eosinophils was regulated by paired immunoglobulin-like receptors PIR-A and PIR-B,” wrote the investigators. “Upon self-recognition of β2-microglobulin (β2M) molecules, PIR-B served as a permissive checkpoint for IL-5–induced development of eosinophils by suppressing the proapoptotic activities of PIR-A, which were mediated by the Grb2-Erk-Bim pathway.”

    “The fundamental knowledge we have gained may one day yield new therapies to treat devastating eosinophilic disorders,” says Ariel Munitz, Ph.D., a researcher at the department of clinical microbiology and immunology at the Sackler School of Medicine at Tel Aviv University and corresponding author of the study.

    Eosinophils are regulated by interleukin 5 (IL-5), a protein that triggers eosinophils to leave the bone marrow and enter the bloodstream, where they can reach various organs. Dr. Munitz and Marc Rothenberg, M.D., Ph.D., director of allergy and immunology at Cincinnati Children's, identified a pathway for counterbalancing what happens when IL-5 triggers eosinophils. The newly identified pathway involves a key checkpoint controlled by a pair of proteins, PIR-A and PIR-B, which the researchers now show have a critical role in eosinophil development.

    PIR-A induces eosinophils to die and thus is in a perpetual tug-of-war with survival and growth signals driven by IL-5. The researchers discovered that PIR-A is dominant in this battle but that cell death doesn't occur because PIR-B inhibits its actions. For PIR-A to win the battle and cause cells to die, PIR-B must be shut down.

    The researchers studied asthmatic mice and discovered that asthmatic mice without PIR-B had little expansion of eosinophils in their blood and lungs and less asthmatic inflammation in their lungs than normal mice. The lack of PIR-B kept eosinophils from reaching harmful levels. The researchers hope that scientists can now target PIR-A to enhance its ability to kill eosinophils or weaken PIR-B so that it inhibits PIR-A to a lesser extent.



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Megamerger Dealzapoppin Poll

What company not in this week’s M&A headlines do you think will be at the center of a megamerger, acquisition, or partial selloff this year?